Skip to content
10-Q

Quarterly Report

Generate Biomedicines, Inc. GENB

0001193125-26-210059

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 29, 2026 128.19M sh
Shares Diluted Q1 2026 · Mar 31, 2026 64.87M sh
Shares Diluted Q1 2026 · Mar 31, 2025 32.79M sh
Capex Q1 2026 · Mar 31, 2026 $3.78M
Capex Q1 2026 · Mar 31, 2025 $751K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$80.39M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$53.18M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $160.58M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $121.65M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $220.61M
Stockholders Equity Q1 2026 · Mar 31, 2026 $514.8M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$615.97M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$471M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$434.52M
Current Liabilities Q1 2026 · Mar 31, 2026 $58.39M
Current Liabilities Q1 2026 · Dec 31, 2025 $82.2M
Total Liabilities Q1 2026 · Mar 31, 2026 $110.94M
Total Liabilities Q1 2026 · Dec 31, 2025 $141.55M
Current Assets Q1 2026 · Mar 31, 2026 $535.39M
Current Assets Q1 2026 · Dec 31, 2025 $234.37M
Total Assets Q1 2026 · Mar 31, 2026 $625.74M
Total Assets Q1 2026 · Dec 31, 2025 $330.18M
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.07
Eps Diluted Q1 2026 · Mar 31, 2025 −$1.62
Eps Basic Q1 2026 · Mar 31, 2026 −$1.07
Eps Basic Q1 2026 · Mar 31, 2025 −$1.62
Sga Expense Q1 2026 · Mar 31, 2026 $13.52M
Sga Expense Q1 2026 · Mar 31, 2025 $10.15M
Rd Expense Q1 2026 · Mar 31, 2026 $57.81M
Rd Expense Q1 2026 · Mar 31, 2025 $46.83M
Rd Expense Q1 2026 · Aug 31, 2021 $10M
Net Income Q1 2026 · Mar 31, 2026 −$61.45M
Net Income Q1 2026 · Mar 31, 2025 −$41.69M
Operating Income Q1 2026 · Mar 31, 2026 −$64.11M
Operating Income Q1 2026 · Mar 31, 2025 −$48.15M
Revenue Q1 2026 · Mar 31, 2026 $7.22M
Revenue Q1 2026 · Mar 31, 2025 $8.82M